This inventor holds 1 USPTO granted patent and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Canbas Co., Ltd.. Active years: 2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2015
Title: Keiichi Sakakibara: Innovator in Cancer Treatment
Introduction
Keiichi Sakakibara is a notable inventor based in Susono, Japan. He has made significant contributions to the field of cancer treatment through his innovative research and development of therapeutic compounds. His work focuses on the use of peptides and peptidomimetics to address cell proliferative disorders.
Latest Patents
Sakakibara holds a patent for "Peptides and peptidomimetics in combination uses and treatments for cancer patient subpopulations." This invention provides compounds that can be utilized to treat various cell proliferative disorders, including those associated with both benign and malignant tumor cells. The compounds function by inhibiting the G2 cell cycle checkpoint, which is crucial for cell growth regulation. This innovative approach allows for the inhibition of cell growth either independently or in conjunction with nucleic acid damaging treatments.
Career Highlights
Keiichi Sakakibara is associated with Canbas Co., Ltd., where he continues to advance his research in cancer therapies. His dedication to improving treatment options for cancer patients is evident in his innovative work and the impact it has on the medical community.
Collaborations
Sakakibara collaborates with talented individuals such as Takumi Kawabe and Naoki Mine. Their combined expertise enhances the research and development efforts at Canbas Co., Ltd.
Conclusion
Keiichi Sakakibara is a pioneering inventor whose work in cancer treatment through peptides and peptidomimetics showcases his commitment to advancing medical science. His contributions are vital in the ongoing fight against cancer, and his innovative spirit continues to inspire others in the field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
